We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

45 hedge funds and large institutions have $307M invested in Foghorn Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

1.69% less ownership

Funds ownership: 65.03% → 63.34% (-1.7%)

4% less funds holding

Funds holding: 47 → 45 (-2)

35% less capital invested

Capital invested by funds: $470M → $307M (-$163M)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
45
Holders Change
-2
Holders Change %
-4.26%
% of All Funds
0.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
3
Increased
12
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$5.75M
2
Deutsche Bank
Deutsche Bank
Germany
+$3.57M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.79M
4
OCA
Octagon Capital Advisors
New York
+$1.13M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$232K

Top Sellers

1
BlackRock
BlackRock
New York
-$3.93M
2
SCM
Suvretta Capital Management
New York
-$2.86M
3
WP
Woodline Partners
California
-$2.09M
4
Victory Capital Management
Victory Capital Management
Texas
-$1.26M
5
Millennium Management
Millennium Management
New York
-$864K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$167M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$33.2M -$125K -7,600 -0.3%
AG
3
Artal Group
Luxembourg
$22.7M – – –
EC
4
Euclidean Capital
New York
$16.6M – – –
CAM
5
Cormorant Asset Management
Massachusetts
$13.2M – – –
MIM
6
Monashee Investment Management
Massachusetts
$6.99M -$488K -29,779 -5%
AI
7
Alphabet Inc
California
$6.6M – – –
BlackRock
8
BlackRock
New York
$5.7M -$3.93M -240,079 -36%
Vanguard Group
9
Vanguard Group
Pennsylvania
$5.37M +$63.6K +3,883 +1%
Morgan Stanley
10
Morgan Stanley
New York
$5.19M +$5.75M +350,978 +821%
BC
11
Birchview Capital
Vermont
$4.14M – – –
Deutsche Bank
12
Deutsche Bank
Germany
$2.94M +$3.57M +217,868 +4,318%
CC
13
Casdin Capital
New York
$2.85M – – –
Millennium Management
14
Millennium Management
New York
$2.14M -$864K -52,744 -25%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$1.93M +$232K +14,128 +11%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$1.44M +$1.79M +109,200 New
State Street
17
State Street
Massachusetts
$1.44M +$120K +7,303 +7%
PAMU
18
Pictet Asset Management (UK)
United Kingdom
$1.29M -$18.9K -1,152 -1%
Northern Trust
19
Northern Trust
Illinois
$1.11M -$67.9K -4,142 -5%
SCM
20
Suvretta Capital Management
New York
$1.11M -$2.86M -174,700 -68%
OCA
21
Octagon Capital Advisors
New York
$911K +$1.13M +69,132 New
Charles Schwab
22
Charles Schwab
California
$628K +$27K +1,647 +4%
BOTOTLSJU
23
Board of Trustees of The Leland Stanford Junior University
California
$404K – – –
JP Morgan Chase
24
JP Morgan Chase
New York
$264K +$6.1K +372 +2%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$256K +$22.2K +1,354 +7%
1
2

FHTX Hedge Fund Activity: Q1 2021 in Review

45 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2021, worth a combined $307M — down 35% from $470M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FHTX and 3 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 12 added.

The largest buyer was Morgan Stanley, adding an estimated $5.75M. The largest seller was BlackRock, cutting an estimated $3.93M.

  • 45 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2021, down from 47 in Q4 2020.
  • Funds reported $307M of Foghorn Therapeutics stock for Q1 2021, down 35% quarter-over-quarter.
  • 3 funds opened new Foghorn Therapeutics positions in Q1 2021 and 5 closed out, a net change of -2 holders.
  • The largest Foghorn Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $5.75M added.
  • The largest Foghorn Therapeutics seller in Q1 2021 was BlackRock, an estimated $3.93M sold.

Based on aggregated 13F filings for Q1 2021.